临界可切除胰腺癌新辅助治疗疗效评价研究进展
Research progress in the response evaluation of neoadjuvant therapy for borderline resectable pancreatic cancer
陈宇 1张革红2
作者信息
- 1. 山西医科大学第一临床医学院,山西 太原 030001
- 2. 山西医科大学第一医院 肿瘤综合科,山西 太原 030001
- 折叠
摘要
胰腺癌是全球癌症死亡的主要原因之一,伴随着经济发展以及肥胖、糖尿病和酒精摄入增加,其发病率不断上升,死亡人数也在逐年增加.根据解剖学特征,胰腺癌被分为可切除胰腺癌、临界可切除胰腺癌、局部进展期胰腺癌和转移性胰腺癌.其中,对于临界可切除胰腺癌,术前行新辅助治疗已显示出巨大的优势,但目前对于新辅助治疗后的疗效评价尚无统一标准,而这关乎胰腺癌患者下一步的诊疗计划.为此,本文基于国内外关于胰腺癌新辅助治疗疗效评价方法的相关研究进展作一综述.
Abstract
Pancreatic cancer is one of the main causes of cancer deaths worldwide.With economic development,obesity,diabetes and increased alcohol intake,its incidence rate is rising,and the number of deaths is also increasing year by year.According to anatomical characteristics,pancreatic cancer can be divided into resectable pancreatic cancer,borderline resectable pancreatic cancer,locally advanced pancreatic cancer and metastatic pancreatic cancer.Among them,neoadjuvant therapy has shown great advantages for borderline resectable pancreatic cancer,but there is no unified standard for efficacy evaluation of neoadjuvant therapy at present,which is related to the next diagnosis and treatment plan for pancreatic cancer patients.Therefore,this article reviews the research progress on the efficacy evaluation method of neoadjuvant therapy for pancreatic cancer at home and abroad.
关键词
临界可切除胰腺癌/新辅助治疗/疗效评价Key words
Borderline resectable pancreatic cancer/Neoadjuvant therapy/Response evaluation引用本文复制引用
出版年
2024
NETL
NSTL
万方数据